Literature DB >> 6227421

Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro.

P Lazarus, J S Germina, M Dufour, G Palmer, D Wallace, L C Panasci.   

Abstract

The uptake of radiolabeled CLZ and CCNU by L1210 leukemia and murine bone marrow cells was investigated to determine whether the preferential ratio of alkylation of L1210 DNA to murine bone marrow DNA of 1.3 by 0.1 mM CLZ, as against a ratio of 0.6 by equimolar CCNU, is secondary to differences in uptake. The concentration of intact CLZ was determined in the medium and the intracellular water space. The cell: medium ratio (intracellular concentration/medium concentration) of CLZ in bone marrow cells was greater than that seen for L1210 cells. However, the intracellular CLZ concentration generally remained constant in both cell types at 37 degrees C, between 7.0 and 10.0 pmole/microliters. The L1210: murine bone marrow cell ratio of intracellular CLZ concentrations was approximately 1.0 from 10 to 60 min. The intracellular CCNU concentration during the uptake of 0.1 mM (chloroethyl-U-14C) CCNU at 37 degrees C was constant at 85 pmol/microliters from 10 to 60 min in L1210 cells, but slowly decreased from 66 pmole/microliters at 20 min to 43 pmole/microliters at 60 min in bone marrow cells. The L1210: murine bone marrow cell ratio of intracellular CCNU concentrations ranged from 1.45 to 1.98 from 20 to 60 min. Thus, it appears that the preferential ratio of alkylation of L1210 DNA to murine bone marrow DNA by CLZ compared with equimolar CCNU cannot be explained by differences in uptake of the two agents by the two cell types. The uptake of 0.1 mM CLZ at 37 degrees C by L1210 cells in McCoy's 5A medium containing 300 mg% glucose was not affected by the addition of 5 mM cold drug, nor was it affected by the absence of glucose in the medium, with or without cold drug. This suggests that CLZ uptake into L1210 cells is via passive diffusion and that CLZ does not enter these cells via the glucose transport mechanism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6227421     DOI: 10.1007/bf00254196

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  An overview of the status of the nitrosoureas in other tumors.

Authors:  S K Carter
Journal:  Cancer Chemother Rep 3       Date:  1973-05

2.  Therapy of advanced gastrointestinal cancer with the nitrosoureas.

Authors:  C G Moertel
Journal:  Cancer Chemother Rep 3       Date:  1973-05

3.  Concentrative uptake of melphalan, a cancer chemotherapeutic agent which is transported by the leucine-preferring carrier system.

Authors:  D T Vistica; M Rabinovitz
Journal:  Biochem Biophys Res Commun       Date:  1979-02-14       Impact factor: 3.575

4.  Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.

Authors:  L C Panasci; D Green; P S Schein
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

5.  Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell.

Authors:  D T Vistica
Journal:  Biochim Biophys Acta       Date:  1979-01-19

6.  Uptake and decomposition of chlorozotocin in L5178Y lymphoblasts in vitro.

Authors:  H Y Lam; M M Talgoy; G J Goldenberg
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

7.  Mechanism of uptake of nitrosoureas by L5178Y lymphoblasts in vitro.

Authors:  A Begleiter; H P Lam; G J Goldenberg
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

  7 in total
  2 in total

1.  Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.

Authors:  L C Panasci; M Dufour; L Chevalier; G Isabel; P Lazarus; A McQuillan; E Arbit; S Brem; W Feindel
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays.

Authors:  P Lazarus; M Dufour; G Isabel; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.